We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
Read MoreHide Full Article
The third-quarter 2022 reporting cycle of the Medical sector has just started. The sector primarily comprises pharma/biotech and medical device companies.
The Earnings Trends report indicates that as of Oct 26, 23.2% of the companies in the Medical sector — representing 43% of the sector’s market capitalization — reported quarterly earnings. While 92% of participants beat on revenues, 84.6% outperformed on earnings. While revenues increased 7.5% year over year, earnings declined 1.8%. Overall, third-quarter earnings of the Medical sector are expected to fall 8.3%, while sales are expected to rise 3.8%.
Throughout the third quarter, most players in the industry reeled under a greater-than-anticipated surge in inflationary pressure across the world. Mounting raw material costs, labor-supply constraints and supply-chain disruptions hampered the entire production and distribution process. Despite the challenging situation, the consistent opening up of economies, with countries lifting COVID-19 restrictions, might have favored the growth process in Q3.
Zeroing in on Winners
Here we have highlighted four MedTech companies — Nevro , Masimo (MASI - Free Report) , Abiomed and Glaukos (GKOS - Free Report) — that are expected to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech/Pharma Stocks That Match the Criteria
Nevro
An uptick in total U.S. permanent implant procedures and trial procedures, and a sequential improvement in PDN trial procedures are likely to have supported Nevro’s top line. Nevro has an Earnings ESP of +10.91% and a Zacks Rank of 2. The Zacks Consensus Estimate for third-quarter loss stands at 71 cents per share.
Nevro beat earnings estimates in two of the last four quarters while beating the mark on one occasion and meeting the same once. NVRO has a trailing four-quarter earnings surprise of 5.73%, on average. Nevro is scheduled to release its third-quarter 2022 results on Nov 2, after market close.
Robust order shipments and expansion of its installed base are likely to have boosted Masimo’s top line during the third quarter. Moreover, the addition of Sound United is likely to have brought additional revenues. Masimo has an Earnings ESP of +4.35% and a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter earnings stands at 92 cents per share.
Masimo beat estimates in each of the last four quarters, delivering an average earnings surprise of 6.96%. MASI is scheduled to release its third-quarter 2022 results on Nov 8, after market close.
Favorable market trends for coronary heart diseases, recent regulatory approvals and robust demand for Abiomed’s products are likely to have been key drivers of its revenues in the soon-to-be-reported quarter. Abiomed has an Earnings ESP of +4.18% and a Zacks Rank #3. The Zacks Consensus Estimate for Abiomed’s third-quarter earnings is pegged at $1.04 per share.
Abiomed beat estimates in each of the last four quarters, delivering an earnings surprise of 10.89%. Abiomed is set to report earnings on Nov 1, before the opening bell.
Solid execution across Glaukos’ global glaucoma and Corneal Health franchises are likely to have helped offset pandemic-induced volatility and global headwinds. Glaukos has an Earnings ESP of +4.03% and a Zacks Rank of 3. The Zacks Consensus Estimate for the third quarter is pegged at a loss of 53 cents per share. Glaukos is scheduled to release results on Nov 2, after market close.
GKOS beat estimates in three of the last four quarters and missed the same once, with the average negative surprise being 7.03%
Image: Bigstock
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
The third-quarter 2022 reporting cycle of the Medical sector has just started. The sector primarily comprises pharma/biotech and medical device companies.
The Earnings Trends report indicates that as of Oct 26, 23.2% of the companies in the Medical sector — representing 43% of the sector’s market capitalization — reported quarterly earnings. While 92% of participants beat on revenues, 84.6% outperformed on earnings. While revenues increased 7.5% year over year, earnings declined 1.8%. Overall, third-quarter earnings of the Medical sector are expected to fall 8.3%, while sales are expected to rise 3.8%.
Throughout the third quarter, most players in the industry reeled under a greater-than-anticipated surge in inflationary pressure across the world. Mounting raw material costs, labor-supply constraints and supply-chain disruptions hampered the entire production and distribution process. Despite the challenging situation, the consistent opening up of economies, with countries lifting COVID-19 restrictions, might have favored the growth process in Q3.
Zeroing in on Winners
Here we have highlighted four MedTech companies — Nevro , Masimo (MASI - Free Report) , Abiomed and Glaukos (GKOS - Free Report) — that are expected to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech/Pharma Stocks That Match the Criteria
Nevro
An uptick in total U.S. permanent implant procedures and trial procedures, and a sequential improvement in PDN trial procedures are likely to have supported Nevro’s top line. Nevro has an Earnings ESP of +10.91% and a Zacks Rank of 2. The Zacks Consensus Estimate for third-quarter loss stands at 71 cents per share.
Nevro beat earnings estimates in two of the last four quarters while beating the mark on one occasion and meeting the same once. NVRO has a trailing four-quarter earnings surprise of 5.73%, on average. Nevro is scheduled to release its third-quarter 2022 results on Nov 2, after market close.
Nevro Corp. Price and Consensus
Nevro Corp. price-consensus-chart | Nevro Corp. Quote
Masimo
Robust order shipments and expansion of its installed base are likely to have boosted Masimo’s top line during the third quarter. Moreover, the addition of Sound United is likely to have brought additional revenues. Masimo has an Earnings ESP of +4.35% and a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter earnings stands at 92 cents per share.
Masimo beat estimates in each of the last four quarters, delivering an average earnings surprise of 6.96%. MASI is scheduled to release its third-quarter 2022 results on Nov 8, after market close.
Masimo Corporation Price and Consensus
Masimo Corporation price-consensus-chart | Masimo Corporation Quote
Abiomed
Favorable market trends for coronary heart diseases, recent regulatory approvals and robust demand for Abiomed’s products are likely to have been key drivers of its revenues in the soon-to-be-reported quarter. Abiomed has an Earnings ESP of +4.18% and a Zacks Rank #3. The Zacks Consensus Estimate for Abiomed’s third-quarter earnings is pegged at $1.04 per share.
Abiomed beat estimates in each of the last four quarters, delivering an earnings surprise of 10.89%. Abiomed is set to report earnings on Nov 1, before the opening bell.
ABIOMED, Inc. Price and Consensus
ABIOMED, Inc. price-consensus-chart | ABIOMED, Inc. Quote
Glaukos
Solid execution across Glaukos’ global glaucoma and Corneal Health franchises are likely to have helped offset pandemic-induced volatility and global headwinds. Glaukos has an Earnings ESP of +4.03% and a Zacks Rank of 3. The Zacks Consensus Estimate for the third quarter is pegged at a loss of 53 cents per share. Glaukos is scheduled to release results on Nov 2, after market close.
GKOS beat estimates in three of the last four quarters and missed the same once, with the average negative surprise being 7.03%
Glaukos Corporation Price and Consensus
Glaukos Corporation price-consensus-chart | Glaukos Corporation Quote
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.